Alpha-synuclein Aggregation in Parkinson's Disease - Is it Relevant and How can we Model it?

Presented at: Neuroscience 2021
C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder with multiple motor and non-motor symptoms. PD is characterized by the presence on proteinaceous neuronal inclusions (Lewy bodies) which are increasingly observed in multiple brain regions during disease progression. One of the main components in Lewy bodies is misfolded α-synuclein. Studies in animal models and PD patients strongly support α-synuclein contribution in PD progression. Inoculation with extracts from PD patients’ brains induces the development and spread of α-synuclein pathology in rodents, non-human primates, and iPSC-derived human neurons. Thus, α-synuclein has emerged as a promising target for developing disease-modifying therapies, aiming at interfering with initial aggregation by small molecules; enhancing degradation of intracellular α-synuclein by stimulating lysosomal activity; lowering cellular α-synuclein levels by anti-sense oligonucleotides and cell-penetrant nanobodies; inhibiting uptake and targeting transmission of extracellular α-synuclein with active and passive immunization. Pre-formed fibrils (PFFs) able to seed aggregation of endogenous α-synuclein in cultured cells and in vivo have become an essential experimental tool to model and study pathological protein aggregation. PFF model allows investigating the uptake of pathogenic fibrils, their internalization, transport, processing and recruitment of endogenous α-synuclein, formation and maturation of Lewy body-like inclusions and effects of these processes on cell function and survival. With α-synuclein PFFs we can study the mechanism of pathology transmission, motor and behavioral outcomes of accumulation of α-synuclein deposits in different brain structures. While the processes of α-synuclein misfolding and pathology progression are still not fully clear, α-synuclein PFFs have been and will be very instrumental for solving these problems.

Learning Objectives:

1. Define main problems in developing disease-modifying therapies for Parkinson’s disease

2. Identify current therapeutic strategies for Parkinson’s disease treatment

3. Analyze benefits and limitations of modelling alpha-synuclein pathology with pre-formed fibrils


Show Resources
You May Also Like
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
JUN 01, 2022 9:00 AM PDT
JUN 01, 2022 9:00 AM PDT
Date: June 01, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) The manufacturing process for cell and gene therapies is complex and can contain process-related impurities from multiple...
Loading Comments...
Show Resources